Abstracts tagged "B-Lymphocyte"

Abstract Number: 0641 • ACR Convergence 2022
IL-4 Receptor Signaling and IKAROS Transcriptomic Program Maintains Naïve B-cell Quiescence and Antagonizes SLE
John Mountz, Min Gao, Shanrun Lui, Walter Chatham and Hui-Chen Hsu, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Factors that promote B-cell quiescence and homeostasis at the transitional (Tr) and naive stages of B cells to prevent excessive TLR7 and type I…
Abstract Number: 1631 • ACR Convergence 2022
Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells
Ken Yasaka¹, Tomohide Yamazaki², Hiroko Sato¹, Tsuyoshi Shirai¹, Hiroshi Fujii¹, Tomonori Ishii³ and Hideo Harigae⁴, ¹Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, ²SBI Biotech, Tokyo, Japan, ³Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan, ⁴Department of Hematology, Tohoku University Hospital, Sendai, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by various autoantibodies. In particular, targeting autoreactive B cells could be a promising therapy with…
Abstract Number: 0644 • ACR Convergence 2022
Long-lived Plasma Cells in the Lupus Bone Marrow Are Imprinted by Interferon
Jennifer Barnas¹, Diana Alzamareh², Neha Nandedkar-Kulkarni², Jennifer Albrecht², Nida Meednu², Cameron Baker², Andrew McDavid¹ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells (PC) play a…
Abstract Number: 1651 • ACR Convergence 2022
CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus
Georg Schett¹, Sebastian Böltz², Fabian Müller², Arnd Kleyer³, Simon Völkl², Michael Aigner², Regina Gary², Sascha Kretschmann², David Simon³, Soraya Kharboutli², Dimitrios mougiakakos⁴, Gerhard Kroenke³ and Andreas Mackensen², ¹Universitätsklinikum Erlangen, Erlangen, Germany, ²FAU Erlangen-Nürnberg, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴University of Magdeburg, Magdeburg, Germany
Background/Purpose: Chimeric antigen receptor (CAR) T cells have been used to treat refractory forms of B cell and plasma cell malignancies. B cells are also…
Abstract Number: 0006 • ACR Convergence 2022
Oral Administration of a Novel Pyrrolopyrimidine Derivative That Inhibits BAFF Signaling Suppresses B Cell Differentiation and Production of Autoantibody in Autoimmune Model Mice
Keiko Yoshimoto¹, Katsuya Suzuki², Yumi Ikeda¹, Tsutomu Takeuchi³ and Yuko Kaneko⁴, ¹Div. of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ²Div. of Rheumatology, Keio University School of Medicine, Shinjuku, Japan, ³Keio University and Saitama Medical University, Tokyo, Japan, ⁴Keio University, Tokyo, Japan
Background/Purpose: We reported that the expression level of a BAFF receptor (BR3) was upregulated in peripheral monocytes of patients with primary Sjogren's syndrome (pSS) and…
Abstract Number: 0754 • ACR Convergence 2022
Persistent but Disturbed Germinal Center Reaction Among 3rd SARS-CoV-2 Vaccination After Rituximab Exposure
Ana-Luisa Stefanski¹, Hector Rincon-Arevalo¹, Eva Schrezenmeier², Franziska Szelinski¹, Jacob Ritter³, Yidan Chen¹, Christian Meisel⁴, Hubert Schrezenmeier⁵, Andreia C. Lino⁶ and Thomas Dörner¹, ¹Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin; DRFZ Berlin; Berlin Institute of Health Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Berlin Institute of Health Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Department of Medical Immunology, Charité University Medicine and Labor Berlin-Charité Vivantes, Berlin, Germany, ⁵Institute of Transfusion Medicine, Ulm University, Ulm, Germany and Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg – Hessen and University Hospital Ulm, Ulm, Germany, ⁶Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: Durable vaccine-mediated immunity relies on the generation of long-lived plasma cells and memory B cells (MBCs), differentiating upon germinal center (GC) reactions. SARS-CoV-2 mRNA…
Abstract Number: 1700 • ACR Convergence 2022
IL-21/STAT3 Pathway Mediated Th2-like Vδ2 T Cells Promote Plasmablasts Differentiation in IgG4-Related Disease
Jieqiong Li¹ and Wen Zhang², ¹Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, ²Peking Union Medical College Hospital, Beijing, China
Background/Purpose: To explore the phenotype and role of gamma delta (γδ) T cells in the pathogenesis of IgG4-related disease (IgG4-RD), focusing on the effect on…
Abstract Number: 0008 • ACR Convergence 2022
CD11c+ T-Bet+ B Cells Traffic to Human Bone Marrow
Jennifer Barnas¹, Diana Alzamareh², Nida Meednu² and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: CD11c+ age/autoimmunity-associated B cells (ABC) are associated with autoantibody producing cells and disease flare in systemic lupus erythematosus. ABC were initially identified in aged…
Abstract Number: 0775 • ACR Convergence 2022
The Distribution and Frequency of Autoreactive B Cells Are Altered in Autoimmune Patients After TNF Inhibitor Treatment
Tam Quach¹, Meggan Mackay², Cynthia Aranow² and Anne Davidson², ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: The development of new autoantibodies and secondary autoimmunity is a common and significant side effect of TNF inhibitors (TNFi) which are widely used to…
Abstract Number: 1713 • ACR Convergence 2022
Bank1 Signaling Shapes the Gut Microbiota Composition by Controlling the Gut Mucosal B-cell Response in Lupus
Georgina Galicia-Rosas, María Botía Sánchez, Daniel Toro-Domínguez, Lorena Albadalejo and Marta Alarcon-Riquelme, Center for Genomics and Oncological Research (GENYO), Granada, Spain
Background/Purpose: Mucosa-associated commensal bacteria have been shown to be involved in the pathogenesis of systemic lupus erythematosus (SLE). However, its exact role remains to be…
Abstract Number: 0011 • ACR Convergence 2022
B Cell Subsets Contributing to the Autoreactive Plasma Cell Pool in Lyn-/- Mice
Kristina Ottens, Jalyn Schneider and Anne Satterthwaite, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by autoantibodies (autoAbs) against nucleic acid containing antigens. These antibodies form immune complexes that promote inflammation and cause organ…
Abstract Number: 0778 • ACR Convergence 2022
TNF Inhibitors Display a Modulatory Effect on Serological and Cellular Vaccine Response in Patients with Chronic Inflamatory Diseases
Ulf Geisen¹, Ruben Rose², Dennis Berner³, Hayley Reid³, Jan Schirmer⁴, Florian Tran⁵, Sascha Gerdes⁶, Stefan Schreiber⁷, Andi Krumbholz¹, Petra Bacher⁷ and Bimba Hoyer¹, ¹UKSH Kiel, Kiel, Germany, ²Dep Infectiology UKSH Kiel, Kiel, Germany, ³Dep Rheumatology and clinical Immunology, UKSH Kiel, Kiel, Germany, ⁴University Medical Center Schleswig-Holstein, Kiel, Germany, ⁵Medical Department, UKSH Kiel, Kiel, Germany, ⁶Dermatology, UKSH Kiel, Kiel, Germany, ⁷Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany
Background/Purpose: Background: The ongoing pandemic is an immunological challenge when using immune modulating drugs. The mRNA vaccines against SARS-CoV-2 are safe and efficient in most…
Abstract Number: 1715 • ACR Convergence 2022
Ezh2 Knockout in B Cells Impairs Plasmablast Differentiation and Ameliorates Lupus-like Disease in MRL/lpr Mice
Xiaoqing Zheng¹, Mikhail Dozmorov², Colleen Strohlein¹, Sheldon Bastacky¹ and Amr Sawalha¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Virginia Commonwealth University, Richmond, VA
Background/Purpose: Enhancer of zeste homolog 2 (EZH2) has been shown to regulate early B cell development and the differentiation of antibody secreting cells (ASCs). We…
Abstract Number: 0012 • ACR Convergence 2022
Role of Type L IFN Signaling on B Cell Pathogenicity in Early Sjögren’s Disease in Mouse Model
Merri-Grace Allred and Scott Lieberman, University of Iowa, Iowa City, IA
Background/Purpose: Sjogren's disease is a chronic autoimmune disease autoimmune disease characterized by foci of inflammation of the lacrimal and salivary glands. As disease progresses, B…
Abstract Number: 0780 • ACR Convergence 2022
B-cell Reconstitution Is Associated with COVID-19 Booster Vaccine Responsiveness in Previously Seronegative Rituximab Treated Rheumatic Disease Patients
Kaitlin Schultz, Deanna Jannat-Khah, DrPH, MSPH and Robert Spiera, Hospital for Special Surgery, New York, NY
Background/Purpose: Booster doses of SARS-CoV-2 vaccines continue to serve as an important strategy for containing the pandemic and may be especially important to rituximab treated…

« Previous Page
1
…
7
8
9
10
11
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].